Company Analysis Arcus Biosciences, Inc.
1. Summary
Advantages
- The stock's return over the last year (33.93%) is higher than the sector average (-26.12%).
- The company's current efficiency (ROE=-66.45%) is higher than the sector average (ROE=-80.94%)
Disadvantages
- Price (18.83 $) is higher than fair price (16.96 $)
- Dividends (0%) are below the sector average (1.24%).
- Current debt level 1% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Arcus Biosciences, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 29.8% | 2.3% | 0.9% |
| 90 days | 7.7% | -36.1% | 9.4% |
| 1 year | 33.9% | -26.1% | 32.4% |
RCUS vs Sector: Arcus Biosciences, Inc. has outperformed the "Healthcare" sector by 60.05% over the past year.
RCUS vs Market: Arcus Biosciences, Inc. has outperformed the market by 1.48% over the past year.
Stable price: RCUS is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: RCUS with weekly volatility of 0.6524% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (18.83 $) is higher than the fair price (16.96 $).
Price is higher than fair: The current price (18.83 $) is 9.9% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (15.42) is lower than that of the sector as a whole (57.99).
P/E vs Market: The company's P/E (15.42) is lower than that of the market as a whole (47.41).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.91) is lower than that of the sector as a whole (9.41).
P/BV vs Market: The company's P/BV (2.91) is lower than that of the market as a whole (22.54).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (11.48) is higher than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (11.48) is lower than that of the market as a whole (15.1).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.22) is lower than that of the sector as a whole (17.44).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.22) is lower than that of the market as a whole (22.02).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 59.64% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (59.64%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-14.25%).
5.4. ROE
ROE vs Sector: The company's ROE (-66.45%) is higher than that of the sector as a whole (-80.94%).
ROE vs Market: The company's ROE (-66.45%) is lower than that of the market as a whole (16.9%).
5.5. ROA
ROA vs Sector: The company's ROA (-28.04%) is lower than that of the sector as a whole (6.66%).
ROA vs Market: The company's ROA (-28.04%) is lower than that of the market as a whole (6.57%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.17%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (7.17%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.24%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 27.03.2024 | Jarrett Jennifer Chief Operating Officer |
Sale | 17.55 | 202 720 | 11 551 |
| 18.03.2024 | Jarrett Jennifer Chief Operating Officer |
Sale | 17.92 | 241 006 | 13 449 |
| 22.09.2023 | Jarrett Jennifer Chief Operating Officer |
Sale | 19.99 | 427 166 | 21 369 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
